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Letter to the BMJ editor
In response to:
Non-absorbable disaccharides for hepatic encephalopathy: systematic review of 
randomised trials
Bodil Als-Nielsen, Lise L Gluud, Christian Gluud
We would like to applaud Bodil Als-Nielson et al. on their excellent 
systematic review of randomised trials using lactulose/lactilol for hepatic 
encephalopathy (HE), (1) which in our opinion has been warranted for some time. We 
agree that non-absorbable disaccharides have been introduced into clinical practice 
without any convincing evidence base, but question the authors’ conclusion that there 
is ‘insufficient evidence’ to determine whether non-absorbable disaccharides are of 
benefit to patients with HE. Surely, this comprehensive review clearly demonstrates 
that lactulose is ‘ineffective’ for treatment of HE rather than there being ‘insufficient 
evidence’. Furthermore, the results of this study have several important implications:
(a) What should comprise standard medical therapy for HE? Lactulose 
should no longer be included, but strict attention should be paid to 
treating the precipitating factors, with correction of dehydration, 
electrolyte and acid-base imbalance, (2) constipation and infection. 
(3) 
(b) A plea for placebo controlled trials: There should be no restriction 
on the conduct of placebo controlled studies on ethical grounds.(c) We need to go back to the drawing board to revisit the interorgan 
metabolism of ammonia and reference the recent studies which 
demonstrate the important roles of the small intestine, muscle and 
kidneys in regulating the blood levels of ammonia. (4)
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